Jänne PA - Search Results

1

Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.

Wittlinger F, Heppner DE, To C, Günther M, Shin BH, Rana JK, Schmoker AM, Beyett TS, Berger LM, Berger BT, Bauer N, Vasta JD, Corona CR, Robers MB, Knapp S, Jänne PA, Eck MJ, Laufer SA. Wittlinger F, et al. Among authors: janne pa. J Med Chem. 2022 Jan 27;65(2):1370-1383. doi: 10.1021/acs.jmedchem.1c00848. Epub 2021 Oct 20. J Med Chem. 2022. PMID: 34668706 Free PMC article.

2

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.

Jänne PA, Taffaro ML, Salgia R, Johnson BE. Jänne PA, et al. Cancer Res. 2002 Sep 15;62(18):5242-7. Cancer Res. 2002. PMID: 12234991

3

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. Paez JG, et al. Among authors: janne pa. Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29. Science. 2004. PMID: 15118125

4

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. Kobayashi S, et al. Among authors: janne pa. N Engl J Med. 2005 Feb 24;352(8):786-92. doi: 10.1056/NEJMoa044238. N Engl J Med. 2005. PMID: 15728811 Free article.

5

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

Jänne PA, Engelman JA, Johnson BE. Jänne PA, et al. J Clin Oncol. 2005 May 10;23(14):3227-34. doi: 10.1200/JCO.2005.09.985. J Clin Oncol. 2005. PMID: 15886310 Review.

6

Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.

Jackman DM, Chirieac LR, Jänne PA. Jackman DM, et al. Among authors: janne pa. Semin Respir Crit Care Med. 2005 Jun;26(3):342-52. doi: 10.1055/s-2005-871993. Semin Respir Crit Care Med. 2005. PMID: 16052436 Review.

7

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA. Mukohara T, et al. Among authors: janne pa. J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94. doi: 10.1093/jnci/dji238. J Natl Cancer Inst. 2005. PMID: 16106023

8

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Johnson BE, Jänne PA. Johnson BE, et al. Among authors: janne pa. Cancer Res. 2005 Sep 1;65(17):7525-9. doi: 10.1158/0008-5472.CAN-05-1257. Cancer Res. 2005. PMID: 16140912 Review.

9

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.

Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Jiang J, et al. Among authors: janne pa. Cancer Res. 2005 Oct 1;65(19):8968-74. doi: 10.1158/0008-5472.CAN-05-1829. Cancer Res. 2005. PMID: 16204070

10

Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.

Jänne PA. Jänne PA. Semin Oncol. 2005 Dec;32(6 Suppl 10):S9-15. doi: 10.1053/j.seminoncol.2005.10.004. Semin Oncol. 2005. PMID: 16459174 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

474 results

Search Page